DICE Therapeutics positive phase 1 data for psoriasis candidate leads shares 71% higher

breakingnow_w51jcqOctober 11, 2022

DICE Therapeutics positive phase 1 data for psoriasis candidate leads shares 71% higher

Read the original article

Previous PostThe case for Joel Embiid for MVP
Next PostThis industry could be worth $180 billion by 2040. Citigroup offers four stock names to play it, and a few more to think about.